SMARTER BIOPSIES, BETTER OUTCOMES
Redefining Precision in Prostate Cancer Care
Triopsy™ Medical, Inc. was founded by leading experts in urology to address a critical gap in prostate cancer diagnosis, where traditional biopsy methods often result in misclassification, overdiagnosis, and unnecessary treatment. Recognizing that diagnostic accuracy is limited by tissue acquisition, not imaging or interpretation alone, Triopsy™ set out to elevate the standard of care through longer, unfragmented tissue sampling and greater procedural control. The result is the Triopsy™ Biopsy System—a patented system combining an adjustable biopsy needle, precision actuator, and Integrated Pathology System (IPS™) to improve accuracy, reproducibility, and patient outcomes, while reducing repeat biopsies and enabling more confident, patient-aligned treatment decisions.
THE CHALLENGE
Traditional prostate biopsies can miss or misclassify disease.
Conventional transrectal ultrasound-guided (TRUS) biopsies often produce small, fragmented tissue samples, making it difficult for urologists to target and capture tissue, for pathologists to interpret results confidently, and for histologists to maintain specimen integrity. This can lead to over- or under-treatment, unnecessary side effects, repeat procedures, and increased uncertainty for both patients and clinicians.
OUR SOLUTION
Triopsy™ captures more tissue for more accurate diagnoses.
The Triopsy™ Biopsy System—including the adjustable biopsy needle, reusable actuator, and Integrated Pathology System (IPS)—empowers urologists to capture longer, intact tissue samples with precision, pathologists to analyze specimens with improved clarity and reproducibility, and histologists to maintain tissue orientation and integrity throughout processing. Together, this system enhances diagnostic accuracy, reduces the need for repeat procedures, and enables more confident, personalized treatment planning for each patient.
Current biopsy methods create critical gaps in prostate cancer diagnosis, where limited precision and control can lead to missed information, inconsistent results, and delayed patient care. As diagnostic decisions demand greater accuracy and reproducibility, the need for improved tissue sampling has become clear. Key limitations of traditional biopsy tools include:
Closing the Gaps in Diagnosis
Short Needles
Provide incomplete samples that can miss critical regions of the prostate, limiting diagnostic accuracy.
Tissue Fragmentation
Reduces diagnostic clarity, lowers reproducibility, and complicates interpretation.
Limited Control
Variability in sample length and orientation can disrupt workflow and reduce consistency in results.
